Biotechnology

3 US Healthcare Stocks That Might Be Undervalued 2025

Healthcare is showing strength in a shaky market—discover which overlooked U.S. stocks could potentially offer upside as the sector regains investor attention.

Medicus Pharma Share Price: MDCX Stock Closed Up 15.35%

Medicus Pharma Share Price Soars: Medicus Pharma closed yesterday at $3.4950, up 15.35% from the previous close of $3.03. Find out all you need to know.

See Why Some Investors Are Watching This Biotech Company

Innovation in healthcare is not just about science. It’s also about the patient experience. One small company is developing a unique treatment.

AstraZeneca Stock (AZN): Transformative Acquisition in Cancer Care

AstraZeneca acquires EsoBiotec for up to $1 billion, enhancing its cancer treatment portfolio with innovative cell therapies.

The Biotech Stocks Tackling the World’s Most Common Cancer

Medicus Pharma (NASDAQ: MDCX) joins Roche, Regeneron, and Bristol-Myers in the 360i BCC market matrix. Discover its breakthrough innovation in skin cancer care.

KalVista Pharmaceuticals Stock (KALV): Advancements in HAE Treatment and Regulatory Progress

KalVista announces promising third quarter results with sebetralstat's progress, pivotal for patients with hereditary angioedema.

TG Therapeutics Stock (TGTX): Advancing MS Treatment

TG Therapeutics announces key data presentations on BRIUMVI, its MS treatment, signaling growth potential for investors.

Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline

Enliven Therapeutics continues to progress in its oncology trials with key Phase 1 data readouts expected in 2025 and a strong cash runway into 2027—discover the latest updates now.

Mineralys Therapeutics Stock (MLYS): Strategic Offering to Fuel Growth

Mineralys Therapeutics has priced a public offering to raise $175 million to advance clinical development of innovative treatments.

Roche Stock (OTC: RHHBY): Strategic Collaboration for Obesity Treatment

Roche partners with Zealand Pharma to co-develop petrelintide, targeting the growing obesity market with promising therapeutic solutions.

Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities

Takeda's revamped oncology strategy prioritizes key tumors and innovative partnerships, enhancing growth prospects and market positioning.

2Seventy Bio (TSVT): Surge Following Acquisition Announcement

2Seventy Bio jumps 77% as Bristol Myers Squibb announces a $5-per-share buyout. Learn how this deal reshapes biotech investing and what it means for you.

Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a revolutionary skin cancer treatment. Key details on this major breakthrough.

FAQs on Medicus Pharma's Interim Data Update - 6 March 2025

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a novel skin cancer treatment. Here are FAQs explaining this breakthrough.

High Demand, Few Options: The Skin Cancer Treatment Gap

Basal Cell Carcinoma is 7x more common than melanoma, yet patients remain underserved. Sun and fair skin fuel its rise. Explore a rising need for treatments.